Compare AAME & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | SNTI |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 29.8M |
| IPO Year | 1995 | 2021 |
| Metric | AAME | SNTI |
|---|---|---|
| Price | $1.71 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 14.1K | ★ 163.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.59 | $0.77 |
| 52 Week High | $3.71 | $2.88 |
| Indicator | AAME | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 57.03 |
| Support Level | $1.59 | $0.88 |
| Resistance Level | $3.15 | $1.19 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 28.00 | 64.66 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).